References
- Copelan E A. Hematopoietic stem-cell transplantation. N Eng J Med 2006; 354: 1813–1826
- Sunwoo J B, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kB, cell survival, tumor growth and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001; 7: 1419–1428
- Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-kB. Ann Rev Biol 1994; 10: 405–455
- Blanco B, Pèrez-Simon J A, Sànchez-Abarca L I, Carvajal-Vergara X, Mateos J, Vidriales B, et al. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 2006; 107: 3575–3583
- Sun K, Welniak L A, Panoskaltsis-Mortari A, O'Shaughnessy M J, Liu H, Barao J, et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci USA 2004; 10: 8120–8125
- Vodanovic-Jankovic S, Hari P, Jacobs P, Komorowski R, Drobyski W R. NF-kappa-B as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145. Blood 2006; 107: 827–834
- Kröger N, Zabelina T, Ayuk F, Atanackovic D, Schieder H, Renges H, et al. Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status. Exp Hematol 2006; 34: 770–775
- Bladè J, Samson D, Reece D, Apperly J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and hematopoietic stem cell tranplantation. Br J Haematol 1998; 102: 1115–1121
- Terpos E, Rezvani K, Basu S, Milne A E, Rose P E, Scott G L, et al. Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma. Eur J Haematol 2005; 75: 376–383
- Rosiñol L, Cibeira M T, Uriburu C, Yantorno S, Salamero O, Bladè J, et al. Bortezomib: an effective agent in extramedullary disease in multiple myeloma. Eur J Haematol 2006; 76: 405–408
- van de Donk N WCJ, Kroger N, Hegenbart U, Corradini P, San Miguel J F, Goldschmidt H, et al. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. Blood 2006; 107: 3415
- Mohty M, Attal M, Marit G, Bulabois C E, Garban F, Gratecos N, et al. Thalidomide salvage therapy following allogenic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myelome (IFM) and the Societe Française de Greffe de Moelle et Therapie cellulaire (SFGM-TC). Bone Marrow Transplant 2005; 358: 165–169
- Koc S, Leisenring W, Flowers M E, Anaselti C, Deeg H J, Nash R A, et al. Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood 2000; 96: 3995–3996
- Rosiñol L, Cibeira M T, Bladè J, Esteve J, Aymerich M, Rozman M, et al. Extramedullary multiple myeloma escapes the effect of thalidomide. Hematologica 2004; 89: 832–836